SUPPLEMENTARY TABLE S2. PARTICIPANT CHARACTERISTICS: 2010–2012 VERSUS 2016–2018

	2010–2012, N=25,529	2016–2018,[a] N=22,697
Age, years, mean±SD	22±17	26±18
Female, n (%)	12,706 (50)	11,394 (50)
Non-Hispanic white, n (%)	20,954 (82)	18,368 (82)
Private insurance, n (%)	17,081 (75)	16,028 (74)
Duration of diabetes, median (IQR)	6 (2–14)	10 (6–19)
BMI z-score, mean±SD	0.4±1.0	0.4±1.0
Pump use, n (%)	12,637 (57)	14,047 (63)
CGM use, n (%)	1591 (7)	6547 (30)
Self-monitoring of blood glucose,[b] mean±SD	4.7±3.0	4.1±2.4
Noninsulin medications for blood glucose control, n (%)		
Metformin	388 (2)	811 (4)
GLP-1 agonist	34 (<1)	300 (1)
DPP-IV*i*	9 (<1)	9 (<1)
SGLT2*i*	0	232 (1)
Pramlintide	124 (<1)	131 (<1)
Other[c]	24 (<1)	28 (<1)

[a]Twelve thousand seven hundred five (56%) participants in the 2016–2018 cohort, also in the 2010–2012 cohort.
[b]Calculation excludes participants using CGM.
[c]Includes thiazolidinediones and sulfonylureas.